Innovative Cardiology offerings aimed at safe, fast and accurate imaging and treatment of the heart
GE Healthcare, a division of General Electric Company (NYSE: GE), today showcased a suite of connected cardiovascular innovations – including several new and advanced imaging technologies and software capabilities – at the 63rd annual American College of Cardiology (ACC) meeting in the “Heart of the Nation,” Washington DC. Ranging from breakthrough Molecular Diagnostics and super-speed Computed Tomography (CT) scans to advanced Cath Labs and patient-friendly Electrocardiograms, GE Healthcare’s show-floor demonstrations in Booth #2126 imagine cardiovascular care that is connected like never before.
"Integration and innovation are vital when developing the next generation of cardiovascular care,” said Tom Gentile, president and CEO of GE Healthcare’s Healthcare Systems. “We’ve worked alongside physicians and patients to produce a new, interconnected portfolio of solutions that truly move the needle when it comes to impacting the quality, affordability and access to care.”
GE Healthcare’s molecular imaging agent AdreView* (Iobenguane I 123 imaging) is now the only FDA-approved molecular imaging agent for scintigraphic assessment of sympathetic innervation of the heart that can be used to help identify adult patients with lower one and two year mortality risk. The heart is supplied with sympathetic nerves that control cardiac conduction. Increased sympathetic nerve activity depletes norepinephrine (NE) storage and can signal heart failure, which may lead to cardiac death. AdreView imaging helps assess NE levels via an external imaging gamma camera.[i] Serious hypersensitivity reactions have been reported following AdreView administration. The most common adverse reactions in NDA clinical trials — dizziness, rash, pruritus, flushing, headache, and injection-site reactions — occurred in <1.3% of patients. [Please see Important Risk and Safety Information for AdreView at the end of this document.]
With Centricity* Cardio Enterprise solution, cardiologists have a single point of access to unified patient data, images and reports across multiple modalities with end-to-end configurable workflows. The solution helps enhance patient care and financial performance by providing full clinical access, improved productivity and revenue cycle efficiencies.
The Centricity Cardio Enterprise solution comprises Centricity Cardio Imaging and Centricity Cardio Workflow. Centricity Cardio Imaging is a web-based cardiovascular PACS that provides access to diagnostic quality images from anywhere with an internet connection to help enable fast, more informed decisions. Centricity Cardio Workflow helps optimize patient care and revenue cycle efficiencies by empowering users to manage the entire cardiovascular department, including scheduling, procedural data monitoring, report generation, billing and inventory management. At ACC, GE Healthcare is introducing an expanded Centricity Cardio Workflow offering, including a new Invasive Peripheral Vascular module to help cardiologists assess, document and report on the patient’s peripheral vessels for a more comprehensive patient view to help inform decision making.
The new MAC* 2000 Resting ECG System with the latest version of Marquette* 12SL* analysis helps avoid variations in care delivery by standardizing ECG information from the physician office through the hospital. The system provides proven diagnostic support enabling clinicians to make fast, accurate diagnoses. Its flexible connectivity solutions offer clinicians the data they need to help improve patient outcomes and streamline workflow throughout the continuum of cardiac care. More information here.
The MUSE* Cardiology Information System is now bi-directionally open to Non-GE electrocardiographs for improved care collaboration and asset management. The MUSE system can now bridge a healthcare system’s ECG investments through bi-directional data sharing with both Non-GE and GE electrocardiographs. This solution offers comprehensive data access for clinicians by integrating ECG data from devices manufactured by vendors such as Philips, Mortara, Nihon Kohden, Edan, and Schiller in addition to GE.
Enabling connectivity to a broader set of ECG assets provides a variety of benefits, including the ability to optimize utilization of current devices. According to Melanie Varin, general manager of US Sales & Marketing, Diagnostic Cardiology, GE Healthcare, “Customers are excited about this opportunity to enable the flow of cardiac information across their enterprise, while extending their current ECG investment.” More information here.
The new app-driven SEER* 1000 Holter Recorder from GE Healthcare utilizes innovative technology to establish patient and physician confidence right from the start. The SEER 1000 is a small, comfortable multi-channel digital Holter recorder paired with the SEER 1000 application for tablets, smartphones or Bluetooth enabled PCs. The system enables fast and accurate patient data entry, visual confirmation of lead placement and a clear view of waveform quality right from initial hookup. The battery life indicator provides an assurance that battery life is adequate prior to beginning a test. One button operation makes it simple for patients to use which may help reduce the number of repeat studies.
No longer are physicians forced to choose between CT systems with wide coverage, high spatial resolution (clear image), or high temporal resolution (speed). GE Healthcare’s 510(k)-pending Revolution CT delivers uncompromised image quality and clinical capabilities through the convergence of coverage, spatial and temporal resolution – all in one. Revolution also enables comprehensive cardiac exams with anatomic and functional information in just one heartbeat – even in challenging patients with higher heart rates.
Dr. Brent Gordon of Loma Linda University utilizes GE’s Innova 3D and Innova HeartVision technologies to confidently manage complex procedures. “The Innova 3D and Innova HeartVision technologies, as well as cardiac analysis tools allow me to quickly define and analyze the anatomy of interest and strategize my intervention with each patient’s unique anatomy in mind,” said Dr. Gordon. “With a single injection, I can feel extremely confident in my measurements, determine optimal gantry angles, and create a virtual model that assists me in real-time through my planned intervention.”
In a featured online case at www.cathlablive.com, Dr. Gordon performs 3D rotational angiography to reconstruct and better characterize Right Ventricular Outflow Tract RVOT morphology and localize branch pulmonary artery origins, as well as to guide stenting of the RVOT, and implantation of a transcatheter pulmonary valve.
Catheter ablation of atrial fibrillation is becoming an increasingly utilized therapy. A Duke Heart Center study of periprocedural imaging in catheter ablation involving more than 11,000 ablations, suggests this procedure’s outcomes improve when combined with adjunct imaging like CT, MR or ultrasound. According to the Duke study, when imaging is paired with atrial fibrillation catheter ablation, patients are at a lower risk for strokes and repeat ablation rates decrease.
“We found significant variation in how physicians image patients before and during AF ablation,” said Dr. Jonathan P. Piccini, assistant professor of medicine at Duke University Medical Center. “The periprocedural imaging was associated with improved outcomes. These findings are hypothesis generating, but highlight the importance of imaging decisions in catheter ablation. Significant opportunities exist to streamline these imaging technologies and to test best practices via prospective studies of multimodality imaging.”
GE Healthcare Ultrasound’s Vivid Cardiovascular Ultrasound systems provide innovative tools designed to help improve workflow efficiency through simplified image acquisition, intuitive navigation and advanced, yet easy to use quantification. Through the company’s XDclear technology, Polar Vision and Depth Illumination communication enhancements, GE Healthcare is empowering healthcare providers with the tools needed to meet the cardiovascular care delivery challenges of today.
*Trademark General Electric Company
[i] AdreView is approved for the scintigraphic assessment of myocardial sympathetic innervation (cardiac nerve activity) to assist in the evaluation of patients with New York Heart Association (NYHA) Class II or Class III heart failure and left ventricular ejection fraction (LVEF) ≤ 35% to help identify patients with one and two-year mortality risks as indicated by an H/M ratio >1.6. In patients with congestive heart failure (CHF), utility has not been established for selecting therapy, monitoring response to therapy, or to identify a patient with high risk of death (AdreView Prescribing Information, GE Healthcare. 2013).Important Risk and Safety Information about AdreView (Iobenguane I 123 Injection)
INDICATIONS: AdreView is a radiopharmaceutical indicated for: (1) use in the detection of primary or metastatic pheochromocytoma or neuroblastoma as an adjunct to other diagnostic tests; and, (2) scintigraphic imaging assessment of sympathetic innervation of the myocardium to assist in the evaluation of adult patients with NYHA class II or class III heart failure and left ventricular ejection fraction <35% to help identify patients with one and two-year mortality risks as indicated by an H/M ratio ≥ 1.6. In patients with congestive heart failure (CHF), utility has not been established for selecting therapy, monitoring response to therapy, or to identify a patient with high risk of death. CONTRAINDICATIONS: AdreView is contraindicated in patients with known hypersensitivity to iobenguane or iobenguane sulfate. WARNINGS AND PRECAUTIONS: Hypersensitivity Reactions: Hypersensitivity reactions have followed AdreView administration. Have anaphylactic and hypersensitivity treatment measures available prior to administration. Benzyl Alcohol Toxicity in Infants: AdreView contains benzyl alcohol, which may cause serious reactions, in premature or low birth-weight infants. Patients with Severe Renal Impairment: As AdreView is cleared by glomerular filtration and is not dialyzable, these patients may have increased radiation exposure and decreased image quality. Thyroid Accumulation: Administer thyroid blockade to patients at risk of thyroid accumulation of AdreView. Medication Withdrawal: Drugs that block norepinephrine uptake or deplete norepinephrine stores, such as some antihypertensive agents, may decrease AdreView uptake and may lead to incorrect imaging results. When medically feasible, stop these drugs before AdreView administration. Hypertension: AdreView may increase release of norepinephrine from chromaffin granules producing transient hypertension. Individuals with Neurological Diseases that Affect the Sympathetic Nervous System: Imaging in these patients may show decreased cardiac uptake independent of heart disease. ADVERSE REACTIONS: Serious hypersensitivity reactions have been reported following AdreView administration. The most common adverse reactions in NDA clinical trials - dizziness, rash, pruritis, flushing, headache and injection site reactions - occurred in < 1.3% of patients. USE IN SPECIFIC POPULATIONS: Pregnancy: Radiopharmaceuticals have potential to cause fetal harm. It is not known whether AdreView can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. AdreView should be given to a pregnant woman only if clearly needed. Nursing Mothers: It is not known whether AdreView is excreted into human milk, however, iodine 123 is excreted into human milk. A decision should be made whether to interrupt nursing after administration of AdreView or not to administer AdreView. Pediatric Use: Safety and effectiveness have not been established in pediatric patients < 1 month of age or in any pediatric patients with CHF. Geriatric Use: Clinical experience has not identified differences in responses between the elderly and younger patients. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection and image interpretation. Consider assessment of renal function in elderly patients prior to AdreView administration.Prior to AdreView administration, please read the Full Prescribing Information.